Literature DB >> 33530254

Esophageal peripheral T-cell lymphoma treated with radiotherapy: A case report.

Qiujing Zhang1, Chengxiang Liu2, Zining Liu3, Menghan Liu4, Chao Xie1, Jinsong Zheng5, Congcong Han1, Dexian Zhang6, Jianjun Zhang1, Shuai Fu1, Jie Liu1.   

Abstract

RATIONALE: The clinical prognosis of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) patients is poor. Therefore, effective treatment is still a challenge at present. Moreover, little is known about the value of radiotherapy in the treatment of PTCL-NOS. PATIENT CONCERNS: A 55-year-old male patient with eating difficulties and progressive exacerbation for 3 months was diagnosed as non-Hodgkin's lymphoma. Airway compression occurred after 2 cycles of first line treatment with cyclophosphamide-Adriamycin-vincristine-prednisone regimen, radiotherapy (48Gy/24f) was given as the second line therapy. DIAGNOSIS: After radiotherapy, the patient complained that mild intermittent dysphagia still existed. Endoscopic biopsy of the upper digestive tract confirmed necrotic material and superficial squamous epithelial mucosa, suggesting esophageal stricture after radiotherapy, which was indistinguishable from tumor residue.
INTERVENTIONS: The patient received anti-inflammatory treatment outside the hospital and did not receive any other special treatment. OUTCOMES: The symptoms of dysphagia disappeared and the focus showed complete response (CR). As of October 1, 2020, the patient has been diagnosed with PTCL-NOS for more than 57 months and the overall survival (OS) have not been achieved. LESSONS: Radiotherapy has obvious and rapid anti-tumor effect on cyclophosphamide-Adriamycin-vincristine-prednisone refractory PTCL-NOS. At the same time, hollow organs after radiotherapy can lead to lumen stenosis and the symptoms of suspected recurrence which is difficult to distinguish only from the imaging findings.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33530254      PMCID: PMC7850710          DOI: 10.1097/MD.0000000000024455

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  10 in total

Review 1.  Peripheral T-cell lymphoma, not otherwise specified.

Authors:  Alessandro Broccoli; Pier Luigi Zinzani
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

2.  Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified.

Authors:  Xi-Mei Zhang; Ye-Xiong Li; Wei-Hu Wang; Jing Jin; Shu-Lian Wang; Yue-Ping Liu; Yong-Wen Song; Hui Fang; Hua Ren; Li-Qiang Zhou; Xin-Fan Liu; Zi-Hao Yu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-09-25       Impact factor: 7.038

3.  Peripheral T-cell lymphoma: novel backbone.

Authors:  Julie M Vose
Journal:  Blood       Date:  2018-01-25       Impact factor: 22.113

Review 4.  Genetic Landscape and Classification of Peripheral T Cell Lymphomas.

Authors:  Rosalind F Sandell; Rebecca L Boddicker; Andrew L Feldman
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

5.  Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

Authors:  Norbert Schmitz; Lorenz Trümper; Marita Ziepert; Maike Nickelsen; Anthony D Ho; Bernd Metzner; Norma Peter; Markus Loeffler; Andreas Rosenwald; Michael Pfreundschuh
Journal:  Blood       Date:  2010-07-21       Impact factor: 22.113

6.  Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.

Authors:  Vivien Mak; Jeremey Hamm; Mukesh Chhanabhai; Tamara Shenkier; Richard Klasa; Laurie H Sehn; Diego Villa; Randy D Gascoyne; Joseph M Connors; Kerry J Savage
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

7.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Authors:  Julie Vose; James Armitage; Dennis Weisenburger
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

8.  T cell lymphoma presenting as esophageal obstruction and bronchoesophageal fistula.

Authors:  Mala Sharma; Wilbert S Aronow; Miechelle O'Brien; Kaushang Gandhi; Harshad Amin; Harit Desai
Journal:  Med Sci Monit       Date:  2011-06

Review 9.  Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification.

Authors:  Parwiz J Siaghani; Joo Y Song
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 4.213

10.  The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project.

Authors:  Monica Bellei; Francine M Foss; Andrei R Shustov; Steven M Horwitz; Luigi Marcheselli; Won Seog Kim; Maria E Cabrera; Ivan Dlouhy; Arnon Nagler; Ranjana H Advani; Emanuela A Pesce; Young-Hyeh Ko; Virginia Martinez; Silvia Montoto; Carlos Chiattone; Alison Moskowitz; Michele Spina; Irene Biasoli; Martina Manni; Massimo Federico
Journal:  Haematologica       Date:  2018-03-29       Impact factor: 9.941

  10 in total
  1 in total

1.  Valproic Acid Inhibits Peripheral T Cell Lymphoma Cells Behaviors via Restraining PI3K/AKT Pathway.

Authors:  Zhiqiang Peng; Jianping Xiong; Hanzhi Dong
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-05       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.